🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

404 results for “treatment” Clear

  1. Treatment as Usual

    Camp4 Therapeutics Corp

    Post-Traumatic Stress Disorder

    phase 2 other completed

    1 trial

  2. Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response.

    The George Institute

    Breast cancer

    phase 2 other active

    1 trial

  3. VLY-686

    Vanda Pharmaceuticals Netherlands B.V.

    Treatment-resistant Pruritus Associated With Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  4. Vancomycin Pre-Treatment

    Seres Therapeutics

    Ulcerative Colitis

    phase 2 small molecule terminated

    1 trial

  5. Venclyxto 100 mg film-coated tablets, RITUXIMAB, Calquence 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, RITUXIMAB, Venclyxto 10 mg film-coated tablets

    AstraZeneca AB

    Treatment Naïve Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  6. X-vivo 15 (serum-free growth medium manufactured under gmp and commercially available from Lonza)

    Biogen

    Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.

    phase 2 small molecule active

    1 trial

  7. YTB323, Flebogamma DIF 50 mg/ml solution for infusion, TOCILIZUMAB, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE

    Novartis Pharmaceuticals

    Treatment-resistant generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  8. Zelboraf 240 mg film-coated tablets

    Ningbo Cancer Hospital

    Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment

    phase 2 small molecule active

    1 trial

  9. conventional therapy plus low dose hUC-MSCs treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 mab completed

    1 trial

  10. idecabtagene vicleucel

    Celgene Europe Limited

    Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)

    phase 2 small molecule active

    1 trial

  11. long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations

    BEONE MEDICINES AUS PTY LTD

    Colorectal Neoplasms

    phase 2 other active

    1 trial

  12. rituximab /Dexamethasone/cyclophosphamide

    The First People's Hospital of Lianyungang

    Treatment

    phase 2 small molecule active

    1 trial

  13. "A study in healthy people to test how 2 different formulations of a combination treatment (vicadrostat and empagliflozin) are taken up in the body and how food influences the amount of the medicines in the blood"

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  14. 610

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    add-on Maintenance Treatment of Patients With Severe Eosinophilic Asthma

    phase 1 small molecule active

    1 trial

  15. 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).

    Teva Pharma GmbH

    Pain

    phase 1 small molecule completed

    1 trial

  16. A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)

    CERO THERAPEUTICS HOLDINGS, INC.

    Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory

    phase 1 other active

    1 trial

  17. A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF CLN-049 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD)

    Cullinan Therapeutics

    Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)

    phase 1 other active

    1 trial

  18. A Phase 1 study to test for safety and activity of an oral investigational drug, in patients with AML or other blood or bone marrow malignacies with an IDH1 mutation.

    The George Institute

    AG-120 is being investigated for the treatment of patients with advanced hematologic malignancies that are IDH1 mutation.

    phase 1 other active

    1 trial

  19. A Phase 1 study to test the safety of an oral investigational drug (either AG-120 or AG-221) in combination with standard chemotherapeutic treatment for patients newly diagnosed with a blood malignancy (AML) with an IDH1 mutation and/or IDH2 mutation

    The George Institute

    Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

    phase 1 other active

    1 trial

  20. A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

    Incyte

    Treatment of participants with MF, MDS, ET, or MDS/MPN

    phase 1 other active

    1 trial

  21. A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

    Enliven Therapeutics

    Chronic myeloid leukemia

    phase 1 other active

    1 trial

  22. A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer

    Amgen

    Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer

    phase 1 other active

    1 trial

  23. A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  24. A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma

    Janssen-Cilag International N.V.

    Multiple myeloma

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources